Research To Practice | Oncology Videos

Latest Episodes:

Acute Myeloid Leukemia | Naval Daver, MD May 14, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia | Faculty Presentation 2: Available and Emerging Nontargeted Therapies for AML — Naval Daver, MD

CME information and select publications

Acute Myeloid Leukemia | Courtney D DiNardo, MD, MSCE May 14, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia | Faculty Presentation 1: Current and Emerging Role of Biomarker-Directed Therapeutic Approaches for Patients with Acute Myeloid Leukemia (AML) — Courtney D DiNardo, MD, MSCE

CME information and select publications

Acute Myeloid Leukemia | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia May 14, 2024

Show notes

Featuring perspectives from Dr Naval Daver and Dr Courtney D DiNardo, including the following topics:

Introduction (0:00)
Available and Emerging Nontargeted Therapies for Acute Myeloid Leukemia (AML) —Dr Daver (6:47)
Current and Emerging Role of Biomarker-Directed Therapeutic Approaches for Patients with AML —Dr DiNardo (32:58)

CME information and select publications

Non-Small Cell Cancer | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Non-Small Cell Lung Cancer with an EGFR Mutation May 10, 2024

Show notes

Featuring perspectives from Ms Marianne J Davies, Dr Alexander I Spira, Ms Jillian Thompson and Dr Helena Yu, including the following topics:

Introduction (0:00)
The Importance of EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) (7:02)
The Role of Osimertinib in Managing Localized and Locally Advanced NSCLC with an EGFR Mutation (11:58)
Established First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (32:38)
Newly Approved and Promising Investigational Approaches to First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (37:45)
Common Toxicities Associated with Amivantamab (45:07)
The Current and Future Management of Progressive NSCLC with an EGFR Mutation (55:06)
Tolerability and Other Practical Considerations with HER3-DXd (1:01:06)
Treatment for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations (1:18:26)

NCPD information and select publications

Metastatic Triple-Negative Breast Cancer | Virtual Case Library: Metastatic Triple-Negative Breast Cancer May 09, 2024

Show notes

Featuring perspectives from Dr Julia Foldi, Dr Laura Huppert, Dr Rita Nanda, Dr Saba Shaikh and Dr Sara M Tolaney, including the following topics:

Introduction: Overview of metastatic triple-negative breast cancer (mTNBC)

Current and emerging strategies for patients with mTNBC (0:00)

First-line treatment of mTNBC — Chemotherapy with or without immunotherapy

Case: A woman in her early 60s with a history of well-controlled HIV is diagnosed with mTNBC — Dr Shaikh (6:10)
Case: A woman in her mid 40s with de novo mTNBC — Dr Huppert (20:41)
Case: A woman in her late 50s with mTNBC receives up-front pembrolizumab/chemotherapy — Dr Foldi (42:15)

Antibody-drug conjugates (ADCs) in the management of mTNBC

ADCs in the management of mTNBC; sequencing of these agents and ongoing investigations (51:45)
Case: A woman in her early 50s with mTNBC receives first-line chemotherapy/immune checkpoint inhibitor followed by sacituzumab govitecan — Dr Shaikh (1:05:32)
Case: A woman in her late 30s with mTNBC receives sacituzumab govitecan — Dr Huppert (1:14:21)
Case: A woman in her early 40s with mTNBC (IHC 1+) with sacituzumab govitecan-intolerant disease experiences an excellent response to trastuzumab deruxtecan (T-DXd) — Dr Foldi (1:27:30)
Case: A woman in her mid 50s with HER2-low metastatic breast cancer receives T-DXd — Dr Shaikh (1:42:00)

PARP inhibition for the treatment of mTNBC

Efficacy and tolerability of olaparib in patients with a germline BRCA mutation and HER2-negative breast cancer (1:49:49)
Case: A woman in her mid 30s with mTNBC receives olaparib — Dr Foldi (1:54:28)
Case: A woman in her mid 60s with mTNBC and a BRCA mutation receives olaparib — Dr Huppert (1:59:11)
Case: A woman in her mid 40s with a BRCA1 germline mutation and mTNBC receives olaparib — Dr Shaikh (2:03:45)

CME information and select publications

Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part Edition May 07, 2024

Show notes

Featuring perspectives from Dr Matthew D Galsky, including the following topics:

HER2 alterations in urothelial cancer and current targeting approaches (0:00)
Key findings supporting the use of trastuzumab deruxtecan for patients with HER2-overexpressing cancers as part of the Phase II DESTINY-PanTumor02 study (9:39)
Targeting of HER2 using disitamab vedotin both as a monotherapy and in combination with other treatments (14:31)
Case: A man in his late 70s with a history of non-muscle-invasive bladder cancer who develops HER2-positive lung metastases (28:57)
Case: A man in his late 60s who receives disitamab vedotin for HER2 IHC 2+ metastatic urothelial cancer (36:25)
Enfortumab vedotin and pembrolizumab as first-line or neoadjuvant therapy for targeting HER2-expressing cancers (39:34)
Future direction of HER2-targeting therapies for urothelial bladder cancer (1:02:48)

CME information and select publications

Gastroesophageal Cancer | Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer (Companion Faculty Lecture) May 03, 2024

Show notes

Featuring a slide presentation and related discussion from Dr Sunnie Kim, including the following topics:

Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer — Dr Kim (0:00)
Case: A man in his mid 50s with poorly differentiated mismatch repair-deficient advanced gastric cancer receives first-line nivolumab/ipilimumab (49:22)
Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma who experienced disease progression on FOLFOX/trastuzumab receives trastuzumab deruxtecan (54:48)
Case: A man in his mid 60s with Stage IV, PD-L1-positive GEJ adenocarcinoma (58:11)
Case: A man in his early 40s with metastatic CLDN18.2-positive gastric/GEJ adenocarcinoma receives zolbetuximab (1:01:10)

CME information and select publications

Gastroesophageal Cancer | Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer May 03, 2024

Show notes

Featuring perspectives from Prof Eric Van Cutsem, including the following topics:

Immune Checkpoint Inhibitors in Localized Gastroesophageal (GE) Cancers

Introduction (0:00)
Case: A man in his mid 50s with localized, poorly differentiated signet ring, mismatch repair-deficient advanced gastric adenocarcinoma — Sunnie Kim, MD (3:39)

HER2-Positive GE Cancers

Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma and disease progression on FOLFOX/trastuzumab (PD-L1 CPS 0) — Dr Kim (19:22)

First-Line Treatment of Metastatic Gastric and GEJ Adenocarcinoma

Case: A man in his early 40s who presents with metastatic GEJ adenocarcinoma (CLDN18.2-positive, PD-L1 CPS 2) in visceral crisis from lung metastases — Dr Kim (38:53)
Case: A man in his mid 60s with metastatic GEJ adenocarcinoma (PD-L1 CPS 20) — Dr Kim (50:50)

CME information and select publications

Myelofibrosis | Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part Series May 02, 2024

Show notes

Featuring perspectives from Dr Ruben A Mesa, including the following topics:

Introduction: Journal Club with Dr Mesa (0:00)
Case: A woman in her mid 80s with an interesting and unusual presentation of primary myelofibrosis — Bhavana (Tina) Bhatnagar, DO (25:33)
Case: A man in his early 70s, asymptomatic, with lower-risk primary MF (JAK2 V617F mutation) — Susannah Friemel, MD (29:42)
Case: A woman in her early 80s with pancytopenia and palpable spleen who is diagnosed with primary MF — Jeanne Palmer, MD (35:08)
Case: A man in his early 70s with multiple comorbidities and MF (CALR mutation) who receives ruxolitinib 10 mg BID — Ranju Gupta, MD (42:40)
ASH 2023 Review (46:13)
Faculty Survey (55:41)

CME information and select publications

Endometrial Cancer | Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Endometrial Cancer May 01, 2024

Show notes

Featuring perspectives from Prof Nicoletta Colombo, Dr Matthew A Powell and Dr Brian M Slomovitz, moderated by Dr Shannon N Westin, including the following topics:

Introduction (0:00)
Current Approaches to First-Line Therapy for Advanced Endometrial Cancer (EC) — Prof Colombo (1:57)
Novel Investigational Strategies for Newly Diagnosed EC — Dr Westin (25:35)
Current Options for Relapsed/Refractory EC — Dr Slomovitz (45:57)
Role of HER2-Targeted Therapy in the Management of Advanced EC — Dr Powell (1:05:54)

CME information and select publications